Unicycive Therapeutics Plunges After FDA Issues Second CRL on Kidney Drug
Unicycive Therapeutics shares plunged nearly 48% in premarket trading Tuesday after the FDA issued a second complete response letter for its kidney disease drug, oxylanthanum carbonate, due to third-party manufacturing issues.
Markets
